Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,160,999

« Back to Dashboard

Details for Patent: 7,160,999

Title:Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
Inventor(s): Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)
Assignee: Emory University (Atlanta, GA)
Filing Date:Aug 20, 2003
Application Number:10/644,293
Claims:1. A method for the resolution of a mixture of the enantiomers of 2-hydroxylmethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), which has the structure ##STR00001## comprising the steps of: (i) providing the mixture of the enantiomers as an 5'-O-acylated derivative of the structure ##STR00002## wherein R is an acyl group; (ii) exposing the 5'-O-acylated derivative of 2-hydroxylmethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane to an enzyme selected from the group consisting of Amano PS-800 lipase and .alpha.-chymotrypsin under conditions that allow selective hydrolysis of the 5'-O-acyl group; and (iii) separating the 5'-O-hydrolyzed enantiomer from the 5'-O-unhydrolyzed enantiomer.

2. The method according to claim 1, wherein the enzyme is Amano PS-800.

3. The method according to claim 1, wherein the enzyme is .alpha.-chymotrypsin.

4. The method of claim 1, wherein R is a residue of an alkyl carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and pentanoic acid.

5. The method of claim 1, wherein R is a residue of a halo-substituted alkyl carboxylic acid selected from the group consisting of 2-chloropropionic acid, 2-chlorobutyric acid and 2-chloropentanoic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
US Army
Argus Health
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus